This morning, the much-anticipated on-site negotiations for the 2024 National Health Insurance Drug List adjustment concluded. According to First Financial News, CAR-T drugs have once again been absent from this round of negotiations, marking the fourth consecutive time they have not participated.

"None of us appeared at the health insurance negotiation site," a representative from a CAR-T company told First Financial News.

The latest negotiations began on October 27, with 25 health insurance negotiation experts divided into five groups, negotiating and bidding for 162 types of drugs. The list of drugs under negotiation included commonly used medications for diabetes, hypertension, and infections, as well as medications for tumors and rare diseases. The final results of the on-site negotiations and bidding will be announced separately.

Earlier, on August 27, the National Health Insurance Administration published a notice regarding the drug list adjustments for the 2024 National Basic Health Insurance, Work Injury Insurance, and Maternity Insurance. The notice revealed that four CAR-T drugs had passed the formal review stage: Fosun Kite's Acilutamide injection, WuXi AppTec's Rukinsan injection, HeYuan Biologics' Nakiyolun injection, and Keji Pharmaceutical's Zevoxin injection.

The interest in whether CAR-T drugs can be included in the health insurance scheme largely stems from their exorbitant prices, nearing or exceeding one million yuan, which limits their accessibility. In the previous three rounds of health insurance negotiations, CAR-T drugs were constrained by the "no negotiations below 500,000, no inclusion below 300,000" rule, ultimately failing to make it to the negotiation table. A representative from a pharmaceutical company indicated to First Financial News that due to production cost constraints, CAR-T drugs will need more time to adjust their pricing for potential inclusion in health insurance payments.

https://finance.eastmoney.com/a/202410303222988354.html